Elsevier Launches New Open Access Journal in Biomedicine: Journal of Clinical and Translational Endocrinology

New York, September 12, 2013

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce the launch of a new open access research publication — Journal of Clinical and Translational Endocrinology (JCTE).

The scope of this new journal is patient-oriented research in a variety of disciplines in endocrinology, including diabetes, metabolic bone disease and osteoporosis, thyroid disease, pituitary and lipid disorders. Areas of high priority include novel pilot/proof-of-concept clinical trials in humans and basic science research involving human specimens.

Dr. Vin Tangpricha from Emory University, Atlanta, Editor-in-Chief of the journal, said, "Journal of Clinical and Translational Endocrinology will provide authors a unique home for manuscripts focused on patient-oriented endocrinology research that translates basic science research to clinical applications for patients with endocrine diseases. As a practicing clinician and a researcher in endocrinology, I understand the importance of strengthening the relationship between the clinical and basic sciences. We look forward to providing the scientific community with high-yield content that addresses the needs of readers and investigators interested in translational research of endocrine diseases."

Andrew Miller, Executive Publisher at Elsevier, added, "Journal of Clinical and Translational Endocrinology will offer the research community a unique and dynamic blend of tradition and innovation: editorial review from an expert team of researchers together with our publishing and dissemination systems, involving innovative, digital approaches. Elsevier is very pleased to launch JCTE and work with Dr. Tangpricha and the journal editors to serve the needs of endocrinologists internationally."

For more information or to submit an article, go to: www.JCTEjournal.com. The journal is ready to accept submissions.  

# # #

About the Editor-in-Chief: Dr. Vin Tangpricha, MD, PhD
Dr. Vin Tangpricha is an Associate Professor of Medicine at Emory University School of Medicine in the Division of Endocrinology, Metabolism and Lipids. He received his M.D. at Tufts University and completed his internal medicine residency and endocrinology fellowship at Boston University Medical Center. He completed a PhD in Molecular Medicine on the topic of colon cancer and vitamin D. Dr. Tangpricha has published a number of manuscripts investigating the role of vitamin D in patients with chronic kidney disease, cystic fibrosis, and infections including HIV and TB. He is currently conducting a number of clinical trials to translate findings from the bench that suggest that vitamin D may play an important role in improving outcomes in patients with infections.
 
About Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as 52 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit www.elsevier.com/openaccess

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Brant Emery
Elsevier
+31 (0)20 485 3310
b.emery@elsevier.com